{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:12:42Z","timestamp":1772791962843,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Systemic juvenile idiopathic arthritis (sJIA) is a complex disease with dysregulation of the innate immune system driven by cytokines. A major role is ascribed to interleukin-1\u03b2 (IL-1\u03b2), supporting the autoinflammatory character of the disease and offering an effective blocking mechanism for treatment. Here we present clinical practice data from the German AID-registry for patients treated with IL-1 inhibition (IL-1i).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In 2009 a clinical and research consortium (AID-Net) was established, including an online AID-registry. Patients with documented sJIA diagnosis were identified. Data for this retrospective IL-1i study were recorded by 17 centers. Response to treatment was evaluated according to Wallace criteria and additionally by an own classifying clinical response system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 6\u2009years, 202 patients with confirmed sJIA were recorded in the AID-registry. Out of these, 111 children received therapy with Anakinra (ANA) (<jats:italic>n<\/jats:italic>\u2009=\u200984, 39 f) and\/or Canakinumab (CANA) (<jats:italic>n<\/jats:italic>\u2009=\u200927, 15 f) at a median age of 8.7 y (range 0.6\u201319.1). During the first 12\u2009months 75\/111 (ANA 55, CANA 20) patients were evaluated according to Wallace criteria (achievement of inactive disease 28\/55 and 17\/20, remission over 6\u2009months under medication 13\/55 and 7\/20 cases). Over the whole period of time, clinical response was preserved in the majority of patients (ANA 54\/80, CANA 20\/27). Arthritis mostly persisted in polyarticular (PA) courses. During treatment with IL-1i concomitant medication could be tapered in about 15%. IL-1i was discontinued in 59\/111 patients. 45 (15) adverse events (AE)s in ANA (CANA) treated patients (19.7 (26.6) AE\/100 ANA (CANA) exposure years, 95%CI: 14.4\u201326.4 (14.9\u201343.9)) were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In a large cohort of sJIA patients from Germany, we can confirm an overall favorable clinical response to both available IL-1 blocking agents. IL-1i was well tolerated with acceptable safety and effectiveness in a real-life clinical setting.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12969-021-00510-8","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T13:02:57Z","timestamp":1616418177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis \u2013 data from the German AID-registry"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-2968","authenticated-orcid":false,"given":"Elke","family":"Lainka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Baehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette","family":"Raszka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes-Peter","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"H\u00fcgle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Foell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claas","family":"Hinze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Weissbarth-Riedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilmann","family":"Kallinich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Windschall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eggert","family":"Lilienthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Niehues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Neudorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Berendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf-Michael","family":"K\u00fcster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad Thomas","family":"Oommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Rietschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Weller-Heinemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Tenbrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg Leonhard","family":"Heubner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Klotsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Wittkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"issue":"1","key":"510_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clim.2015.04.018","volume":"159","author":"N Bruck","year":"2015","unstructured":"Bruck N, Schnabel A, Hedrich CM, et al. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (SJIA) and target-directed therapeutic approaches. Clin Immunol. 2015;159(1):72\u201383.","journal-title":"Clin Immunol"},{"key":"510_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/AHMT.S109495","volume":"8","author":"S Grevich","year":"2017","unstructured":"Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther. 2017;8:125\u201335.","journal-title":"Adolesc Health Med Ther"},{"issue":"2","key":"510_CR3","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"1","key":"510_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Holzinger D, Lainka E, Haas JP, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J. 2018;16(1):7. https:\/\/doi.org\/10.1186\/s12969-018-0224-2.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"510_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clim.2011.10.003","volume":"142","author":"G Dueckers","year":"2012","unstructured":"Dueckers G, Guellac N, Arbogast M, Dannecker G, et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol. 2012;142(2):176\u201393.","journal-title":"Clin Immunol"},{"issue":"7","key":"510_CR6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s12098-019-02985-6","volume":"86","author":"NK Bagri","year":"2019","unstructured":"Bagri NK. Cyclosporine for sJIA: current stand and future directions. Indian J Pediatr. 2019;86(7):576\u20137. https:\/\/doi.org\/10.1007\/s12098-019-02985-6.","journal-title":"Indian J Pediatr"},{"issue":"2","key":"510_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, Beresford MW, et al. Pediatric rheumatology international trials organization (PRINTO). Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2):190\u20137. https:\/\/doi.org\/10.3899\/jrheum.180168.","journal-title":"J Rheumatol"},{"key":"510_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1546-0096-10-40","volume":"10","author":"S Kumar","year":"2012","unstructured":"Kumar S, Kunhiraman DS, Rajam L, et al. Application of the Yamaguchi criteria for classification of \u201csuspected\u201d systemic juvenile idiopathic arthritis (SJIA). Pediatr Rheumatol. 2012;10:40. https:\/\/doi.org\/10.1186\/1546-0096-10-40.","journal-title":"Pediatr Rheumatol"},{"issue":"12","key":"510_CR9","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1002\/art.39796","volume":"68","author":"J Klotsche","year":"2016","unstructured":"Klotsche J, Raab A, Niewerth M, Sengler C, et al. Outcome and trends in treatment of systemic juvenile idiopathic arthritis in the German National Pediatric Rheumatologic Database, 2000-2013. Arthritis Rheumatol. 2016;68(12):3023\u201334.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"510_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12969-018-0236-y","volume":"16","author":"M Bielak","year":"2018","unstructured":"Bielak M, Husmann E, Weyandt N, Haas JP, et al. IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry). Pediatr Rheumatol Online J. 2018;16(1):22. https:\/\/doi.org\/10.1186\/s12969-018-0236-y.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"510_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/art.33342","volume":"64","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Quartier P, Wulffraat N, Woo P, et al. Pediatric rheumatology international clinical trials organisation. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64(2):557\u201367. https:\/\/doi.org\/10.1002\/art.33342.","journal-title":"Arthritis Rheum"},{"issue":"25","key":"510_CR12","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T. Et al; PRINTO; PRCSG. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1205099.","journal-title":"N Engl J Med"},{"issue":"25","key":"510_CR13","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, et al. PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395. https:\/\/doi.org\/10.1056\/NEJMoa1112802 Erratum in: N Engl J Med 2015; 372(9): 887.","journal-title":"N Engl J Med"},{"key":"510_CR14","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, Holzinger D, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66:1034\u201343.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"510_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH, Zeft A, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545\u201355.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"510_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00393-020-00779-2","volume":"79","author":"D Foell","year":"2020","unstructured":"Foell D, Wittkowski H, Hinze C. Still\u2019s disease as biphasic disorder: current knowledge on pathogenesis and novel treatment approaches. Z Rheumatol. 2020;79(7):639\u201348.","journal-title":"Z Rheumatol"},{"issue":"1","key":"510_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/rheumatology\/keq270","volume":"50","author":"E Lainka","year":"2011","unstructured":"Lainka E, Bielak M, Hilger V, et al. Translational research network and patient registry for auto-inflammatory diseases. Rheumatology (Oxford). 2011;50(1):237\u201342.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"510_CR18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","volume":"64","author":"EM DeWitt","year":"2012","unstructured":"DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64(7):1001\u201310.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"510_CR19","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19(3):424\u201330.","journal-title":"J Rheumatol"},{"key":"510_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0031-1275747","volume":"36","author":"JP Haas","year":"2011","unstructured":"Haas JP, et al. Systemic onset juvenile idiopathic arthritis \u2013 at the borderline between autoinflammation and autoimmunity. Akt Rheumatol. 2011;36:236\u201341.","journal-title":"Akt Rheumatol"},{"issue":"12","key":"510_CR21","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1002\/art.39784","volume":"68","author":"F Gohar","year":"2016","unstructured":"Gohar F, Orak B, Kallinich T, Jeske M, Lieber M, et al. Correlation of secretory activity of neutrophils with genotype in patients with familial Mediterranean fever. Arthritis Rheumatol. 2016;68(12):3010\u201322. https:\/\/doi.org\/10.1002\/art.39784.","journal-title":"Arthritis Rheumatol"},{"key":"510_CR22","first-page":"2290","volume":"31","author":"CA Wallace","year":"2004","unstructured":"Wallace CA, Ruperto N, Giannini E. Preliminary criteria remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290\u20134.","journal-title":"J Rheumatol"},{"issue":"1","key":"510_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","volume":"19","author":"G Horneff","year":"2017","unstructured":"Horneff G, Schulz AC, Klotsche J, Hospach A, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"510_CR24","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasigli\u00e8 D, Tassi S, Brisca G, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(5):1505\u201315.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"510_CR25","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"V Pascual","year":"2005","unstructured":"Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479\u201386.","journal-title":"J Exp Med"},{"issue":"5","key":"510_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747\u201354. https:\/\/doi.org\/10.1136\/ard.2010.134254.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"510_CR27","doi-asserted-by":"publisher","first-page":"e000036","DOI":"10.1136\/rmdopen-2014-000036","volume":"1","author":"A Woerner","year":"2015","unstructured":"Woerner A, Uettwiller F, Melki I, et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open. 2015;1(1):e000036. https:\/\/doi.org\/10.1136\/rmdopen-2014-000036 eCollection 2015.","journal-title":"RMD Open"},{"issue":"7","key":"510_CR28","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/art.40867","volume":"71","author":"LA Henderson","year":"2019","unstructured":"Henderson LA. A Bullseye for children with systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2019;71(7):1030\u20133. https:\/\/doi.org\/10.1002\/art.40867.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"510_CR29","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","volume":"77","author":"N Ruperto","year":"2018","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. 2018;77(12):1710\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213150.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"510_CR30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40.865","volume":"71","author":"NM Ter Haar","year":"2019","unstructured":"Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, et al. Treat-to-target using first-line recombinant interleukin-1 receptor antagonist monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five year follow-up study. Arthritis Rheumatol. 2019;71(7):1163\u201373. https:\/\/doi.org\/10.1002\/art.40.865.","journal-title":"Arthritis Rheumatol"},{"key":"510_CR31","doi-asserted-by":"publisher","unstructured":"Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicentre retrospective observational study. Clin Rheumatol. 2018. https:\/\/doi.org\/10.1007\/s10067-018-4119-x.","DOI":"10.1007\/s10067-018-4119-x"},{"key":"510_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-015-0228-7","volume":"10","author":"L Rossi-Semerano","year":"2015","unstructured":"Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, et al. MAIL1 (maladies auto-inflammatoires et anti-IL-1) study group on behalf of CRI (Club Rhumatisme et inflammation). Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19\u201330. https:\/\/doi.org\/10.1186\/s13023-015-0228-7.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"510_CR33","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","volume":"25","author":"CA Dinarello","year":"2013","unstructured":"Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25(6):469\u201384.","journal-title":"Semin Immunol"},{"issue":"1","key":"510_CR34","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/art.39407","volume":"68","author":"AA Grom","year":"2016","unstructured":"Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, Ruperto N. Pediatric rheumatology international trials organisation and the pediatric rheumatology collaborative study group, Leon K, Lheritier K, Abrams K. rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with Canakinumab. Arthritis Rheumatol. 2016;68(1):218\u201328. https:\/\/doi.org\/10.1002\/art.39407.","journal-title":"Arthritis Rheumatol"},{"key":"510_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1546-0096-12-28","volume":"12","author":"B H\u00fcgle","year":"2014","unstructured":"H\u00fcgle B, Hinze C, Lainka E, Fischer N, Haas JP. Development of positive antinuclear antibodies and rheumatoid factor in systemic juvenile idiopathic arthritis points toward an autoimmune phenotype later in the disease course. Pediatr Rheumatol Online J. 2014;12:28. https:\/\/doi.org\/10.1186\/1546-0096-12-28.","journal-title":"Pediatr Rheumatol Online J"},{"key":"510_CR36","doi-asserted-by":"publisher","unstructured":"Saccomanno B, Tibaldi J, Minoia F, Bagnasco F, Pistorio A, et al. Predictors of effectiveness of anakinra in Systemic Juvenile Idiopathic Arthritis. J Rheumatol. 2019:180331. https:\/\/doi.org\/10.3899\/jrheum.180331.","DOI":"10.3899\/jrheum.180331"},{"key":"510_CR37","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/DDDT.S114532","volume":"12","author":"N Toplak","year":"2018","unstructured":"Toplak N, Blazina S, Avcin T. The role of IL-1 inhibition in systemic idiopathic arthritis: current status and future persectives. Drug Des Devel Ther. 2018;12:1633\u201343.","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"510_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","volume":"55","author":"S Tarp","year":"2016","unstructured":"Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JM, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55(4):669\u201379.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"510_CR39","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/art.21774","volume":"54","author":"D Singh-Grewal","year":"2006","unstructured":"Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006;54(5):1595\u2013601.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"510_CR40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/1740774518761367","volume":"15","author":"PA Nigrovic","year":"2018","unstructured":"Nigrovic PA, Beukelman T, Tomlinson G, Feldman BM, Schanberg LE, Kimura Y. Childhood arthritis and rheumatology research Alliance systemic juvenile idiopathic arthritis consensus treatment plan workgroup. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-line options for systemic juvenile idiopathic arthritis treatment (FROST). Clin Trials. 2018;15(3):268\u201377.","journal-title":"Clin Trials"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00510-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-021-00510-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00510-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T14:52:18Z","timestamp":1724683938000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00510-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00510-8","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"23 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The AID-registry has been approved by the ethics committees and the data protection responsibles at the University of Duisburg-Essen and Muenster, as well as the Medical Association Nordrhein in Duesseldorf. Parents, children between 9 and 13\u2009years of age and young patients aged \u226514\u2009years provide informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval and consent to participate"}},{"value":"Each author listed on the manuscript has approved the submission of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EL received speaker honoraria from Novartis and SOBI. TK received speaker honoraria from Novartis, SOBI and Roche as well as research report from Novartis. HW received speaker honoraria from Novartis, Shire\/Takeda and CSL-Behring. GH received support for scientific studies from Abbvie, Chugei, MSD, Novartis, Pfizer, Roche and honoraria from Abbvie, Chugai, GSK, Pfizer and Novartis. UN received speaker honoraria from Roche and support for 2 meetings by SOBI. PTO received research funding from Novartis. KT received support from SOBI, grants from Pfizer and Novartis Medical Foundation. CH received honoraria from Novartis. RB, CR, TL, BH, NF, MB, BR, RMK, JK, JPH, EL, GLH declare that they have no conflict of interest. DW received speaker honoraria from Abbvie and Pfizer as well as research support from Novartis and Roche. DF received speaker honoraria from Novartis, SOBI and Roche as well as research report from Novartis, SOBI and Pfizer.EWR received honoraria for advisory boards and travel support from Novartis, SOBI and Roche. FWH received speaker honoraria from Novartis, SOBI and Roche. TN received authorship fees from(Wellesley, Massachusetss, USA) and reimbursement of travel expenses during consultancy work from European Medicines Agency (EMA), steering committees of the PENTA (Pediatric European Network For Treatment of AIDS) (Padua, Italy), the Juvenile Inflammatory Cohort (JIR) (Lausanne, Switzerland), and, until 2017, the FIND-ID Initiative (supported by the Plasma Protein Therapeutic Association (PPTA) (Brussels, Belgium).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}